このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

AlzeCure Pharma 過去の業績

過去基準チェック /06

AlzeCure Pharmaは2%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで8.4%毎年増加している。売上は成長しており、年平均101.9%の割合である。

主要情報

2.0%

収益成長率

10.9%

EPS成長率

Pharmaceuticals 業界の成長	30.5%
収益成長率	101.9%
株主資本利益率	-267.9%
ネット・マージン	n/a
次回の業績アップデート	26 Aug 2024

Recent updates

Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

Feb 03

We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate

Dec 13

収支内訳

AlzeCure Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OM:ALZCUR 収益、費用、利益 ( )SEK Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	0	-37	11	28
31 Dec 23	0	-37	11	28
30 Sep 23	0	-38	10	29
30 Jun 23	0	-42	10	32
31 Mar 23	0	-53	10	43
31 Dec 22	0	-56	10	46
30 Sep 22	0	-68	10	58
30 Jun 22	0	-73	10	63
31 Mar 22	0	-67	10	57
31 Dec 21	0	-78	11	67
30 Sep 21	0	-73	11	62
30 Jun 21	0	-78	10	68
31 Mar 21	0	-81	10	71
31 Dec 20	0	-71	9	62
30 Sep 20	0	-69	9	61
30 Jun 20	0	-61	8	53
31 Mar 20	0	-53	7	46
31 Dec 19	0	-51	6	45
30 Sep 19	0	-48	5	44
30 Jun 19	-2	-40	4	38
31 Mar 19	-1	-38	4	37
31 Dec 18	0	-36	3	37
30 Sep 18	1	-28	-3	34
31 Dec 17	1	-10	1	10

質の高い収益: ALZCURは現在利益が出ていません。

利益率の向上: ALZCURは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ALZCURは利益を出していないが、過去 5 年間で年間2%の割合で損失を削減してきた。

成長の加速: ALZCURの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ALZCURは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 1.2% ) と比較することは困難です。

株主資本利益率

高いROE: ALZCURは現在利益が出ていないため、自己資本利益率 ( -267.9% ) はマイナスです。

AlzeCure Pharma 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

AlzeCure Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 04, 2024

AlzeCure Pharma AB (publ) to Report Q4, 2023 Results on Feb 27, 2024

AlzeCure Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

AlzeCure Pharma AB (publ) to Report Q2, 2021 Results on Aug 25, 2021

AlzeCure Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 28, 2021

Recent updates

Alzecure Pharma AB (Publ) Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

Price target decreased by 10% to kr13.00

AlzeCure Pharma AB (publ) Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024

New major risk - Market cap size

AlzeCure Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 52.77396 million.

AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference

AlzeCure Pharma AB (publ) Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's

New minor risk - Share price stability

AlzeCure Pharma AB (publ) Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference

AlzeCure Pharma AB (publ) Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain

We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth

AlzeCure Pharma AB (publ) Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD

AlzeCure Pharma AB (publ) Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856

Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference

AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference

AlzeCure Pharma AB (publ) Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference

AlzeCure Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 04, 2024

New minor risk - Financial position

AlzeCure Pharma AB (publ) to Report Q4, 2023 Results on Feb 27, 2024

AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's

Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth

AlzeCure Pharma AB (Publ) Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders

Alzecure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-Opioid ACD440

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

Forecast to breakeven in 2025

Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440

AlzeCure Pharma AB (publ) Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's

Alzecure Pharma AB (Publ) Gets Abstract Accepted on New Potential Disease-Modifying Effects of ACD856 Against Alzheimer's

AlzeCure Pharma AB (publ) Gets Late-Breaking Abstract on New Data with Alzheimer Project

Alzecure Pharma AB (Publ) Announces New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented At Alzheimer's Conference CTAD

Alzheimer Announces New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856

Price target decreased to kr12.00

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Positive Clinical EEG Results with Alzheimer's Project NeuroRestore ACD856

Price target decreased to kr12.00

Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?

AlzeCure Pharma AB (publ) Announces New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856

AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain Project at IASP 2022

AlzeCure's Alzheimer’s Project NeuroRestore ACD856 Shows Positive Effect on Brain Activity in Clinical Trial

AlzeCure Pharma AB (publ), Annual General Meeting, May 17, 2023

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Potential Neuroprotective Effects of NeuroRestore ACD856

AlzeCure Pharma AB Gets Abstract on New Clinical Study Data with NeuroRestore Accepted At the Alzheimer's Conference Aaic

AlzeCure Pharma AB (Publ) Announces Update on Clinical Phase I Study

AlzeCure Pharma AB (publ) Announces First Patient Included in its Phase II Clinical Trial in Neuropathic Pain with Non-Opioid ACD440

Alzecure Pharma AB (Publ)'s Abstract on Pain Project TrkA-NAM Accepted for Presentation At IASP 2022

AlzeCure Pharma AB (publ) Gets Approval to Start Phase II Clinical Trial with Non-Opioid Pain Project ACD440

AlzeCure Pharma AB (publ) Publishes New Data on Alzstatin from Alzheimer Conference

AlzeCure Publishes New Data on NeuroRestore and Acd856 from Alzheimer's Conference

Chief Executive Officer recently bought kr163k worth of stock

Chief Executive Officer recently bought kr163k worth of stock

Chief Financial Officer recently bought kr120k worth of stock

Alzecure Pharma AB (Publ) Receives Positive Indicative Clinical Data with Acd856 in Development for Alzheimer's Disease

Alzecure Pharma AB (publ) Announces Moving Towards Phase IIa Clinical Trial with ACD440 Based on Guiding Response from the FDA

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Price target increased to kr21.90

AlzeCure Pharma AB (publ) to Present Abstract at ECNP Conference on NeuroRestore Project's Potential in Depression

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

AlzeCure Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

AlzeCure Pharma AB (publ) to Report Q2, 2021 Results on Aug 25, 2021

New 90-day low: kr7.50

Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

New 90-day low: kr8.16

We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate

Chief Financial Officer recently bought kr96k worth of stock

Chief Financial Officer recently bought kr96k worth of stock

AlzeCure Pharma AB (publ), Annual General Meeting, May 12, 2021

AlzeCure Pharma AB (publ) Receives Approval to Start Clinical Phase I Trial with ACD856 in Alzheimer's Disease

New 90-day high: kr11.60

過去基準チェック /06